Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.

Abstract: Electroacoustic device having a transducer including a piezoelectric substrate, first and second electrodes of inverse polarity having respective first and second tracks provided on said substrate, the first and second tracks spiraling around a same center (C), the transducer being configured for generating a swirling ultrasonic surface wave in the substrate.

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

Abstract: The invention discloses a method to measure end-to-end and partial latency between an input interface and an output interface of a processing device. The invention uses a generator of a calibrated output to be output by the processing device through the output interface and a sensor configured to capture the calibrated output and send it to a processing unit of the processing device through the input interface. An advantageous arrangement of a calibrated output is a specific texture to be output by a screen and captured by an optical sensor. A specific texture comprises elementary patterns which have a defined number of pixels and a defined proportion and location of dark and light pixels. According to certain aspects of the invention, a calibration of latency is performed based on a number of parameters defining the hardware and/or software configuration of the processing device, and/or its conditions of operation.

Abstract: The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

Abstract: Method for preparing a peptide assembly of n fragments and n?1 amino acids bearing a thiol function, represented by the formula: A1-C1-A2-C2-A3- . . . -Ci?1-Ai- . . . -Cn?1-An??(I) in which A1, A2, A3, . . . Ai . . . , An are peptide fragments, C1, C2, C3 . . . Ci?1 . . . Cn?1 are amino acid residues bearing a thiol function, n is comprised between 3 and 50, and i is 2 to n, in which a peptide-thioester is prepared of formula: A1-SR (II) in which A1 is a peptide fragment and SR is an alkyl thioester residue, R being alkyl optionally substituted, starting from a bis(2-sulphanylethyl)amino peptide.

Abstract: An anastomosis device for joining hollow lumens or viscera, suitable for deployment at the surface of two superposed adjacent lumens. The device has a main tubular body of longitudinal axis (L), having first and second open ends and opposite outside and inside faces. The main tubular body has at least three columns of loops and at least three rows of loops and sets of proximal and distal radial projections extending along at least a depth (E) at the peripheries of the first and second ends respectively. The distal and proximal sets are spaced apart by a minimum internal distance (D), and further include a set of intermediate radial projections extending along at most a depth (e) and arranged between the sets of proximal and distal radial projections. The depth (e) is less than (E), and the minimum internal distance (D) is determined so as to receive two superposed adjacent lumens.

Abstract: The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.

Abstract: The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.

Abstract: The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.

Abstract: A method refocuses on an optical assembly target surface, using at least one beam originating from a short-pulse optical source, having at least one optical system for focusing the beam on the surface. Refocusing occurs after learning reference conditions for which the assembly is considered as focused. A focusing signal is detected representing a time overlap of the pulses between a beam reflected and a reference beam not reflected by the surface and comes from the source, one of the beams delayed by a delay line, the beam optical path on which the delay line is placed is varied, on the basis of the reference conditions, to cause the focusing signal to reach or go beyond a predetermined threshold. The focus is adjusted on the basis of variation knowledge in the path between the reference conditions and the conditions for which the focusing signal reaches or goes beyond the threshold.

Abstract: The present invention relates to a compound according to Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, and its use.

Abstract: The invention relates to a device for detecting analytes, including a plastic substrate at least partially covered by bonding polymers attached to the substrate in a non-covalent manner, said bonding polymers comprising a polysaccharide backbone provided with aromatic groupings and carboxylic acid groupings.

Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with iNKT cell agonists.

Abstract: A process for the preparation by ethylene polymerization of at least one dialkyl magnesium compound of formula R—(CH2—CH2)n—Mg—(CH2—CH2)m—R? in which R and R?, identical or different, represent aryl, benzyl, allyl or alkyl groups and in which the integers n and m, identical or different, represent average —CH2—CH2— chain formation numbers greater than 1, the process including a single stage of mixing the following components: at least one ligand or one ligand precursor, at least one rare earth salt, at least one dialkyl magnesium compound of formula R—Mg—R?, and ethylene, in a medium allowing contact between the components of the above mixture.

Abstract: Method for preparing a peptide assembly of n fragments and n?1 amino acids bearing a thiol function, represented by the formula: A1-C1-A2-C2-A3- . . . -Ci?1-Ai- . . . -Cn?1-An ??(I) in which A1, A2, A3, . . . Ai . . . An are peptide fragments, C1, C2, C3 . . . Ci?1 . . . Cn?1 are amino acid residues bearing a thiol function, n is comprised between 3 and 50, and i is 2 to n, in which a peptide-thioester is prepared of formula: A1-SR (II) in which A1 is a peptide fragment and SR is an alkyl thioester residue, R being alkyl optionally substituted, starting from a bis(2-sulphanylethyl)amino peptide.

Abstract: The invention relates to a device for detecting analytes, including a plastic substrate at least partially covered by bonding polymers attached to the substrate in a non-covalent manner, said bonding polymers comprising a polysaccharide backbone provided with aromatic groupings and carboxylic acid groupings.

Abstract: The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy.

Abstract: A wireless data transmitter including: a data modulator adapted to modulate a data signal based on a frequency signal; and at least one antenna adapted to wirelessly transmit the modulated data signal and the frequency signal independently.